Sara E Runnion Lewton, LMLP in Pratt, KS - Psychologist

Sara E Runnion Lewton, LMLP is a Psychologist based in Pratt, Kansas. Sara E Runnion Lewton is licensed to practice in Kansas (license number 915) and her current practice location is 101 E 8th St, Pratt, Kansas. She can be reached at her office (for appointments etc.) via phone at (620) 672-2332.

NPI number for Sara E Runnion Lewton is 1275633927 and her current mailing address is 100 Robinson Ave, Coats, Kansas. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1275633927.

Contact Information

	Sara E Runnion Lewton, LMLP
	101 E 8th St, Pratt, KS 67124-2867
	(620) 672-2332
	Not Available

Healthcare Provider's Profile

Full Name	Sara E Runnion Lewton
Gender	Female
Speciality	Psychologist
Location	101 E 8th St, Pratt, Kansas
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1275633927
Provider Enumeration Date: 09/23/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Sara E Runnion Lewton such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1275633927	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
103T00000X	Psychologist	915 (Kansas)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Sara E Runnion Lewton is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Sara E Runnion Lewton, LMLP 100 Robinson Ave, Coats, KS 67028-9414 Ph: () -	Sara E Runnion Lewton, LMLP 101 E 8th St, Pratt, KS 67124-2867 Ph: (620) 672-2332

News Archive

FDA grants BrainStorm's NurOwn orphan drug designation for treatment of ALS

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's NurOwn™ autologous adult stem cell product candidate for the treatment of amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's Disease.

Researchers identify several previously unknown antibiotic resistance genes

Researchers at Chalmers University of Technology and the University of Gothenburg, Sweden, have found several previously unknown genes that make bacteria resistant to last-resort antibiotics.

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

Researchers develop cancer vaccine platform to improve efficacy of oncolytic enveloped viruses

Researchers at the Faculty of Pharmacy have developed PeptiENV, a cancer vaccine platform, which can be used to improve the therapeutic efficacy of oncolytic enveloped viruses currently in clinical use.

Sara E Runnion Lewton, LMLP - Psychologist in Pratt, KS